AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Liberum Capital

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reiterated by stock analysts at Liberum Capital in a report issued on Wednesday, ThisIsMoney.Co.Uk reports.

A number of other analysts have also commented on the company. Bryan, Garnier & Co reiterated a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Barclays set a GBX 7,600 ($99.31) price objective on AstraZeneca and gave the stock a “buy” rating in a research report on Friday, August 9th. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a research report on Friday, July 26th. Goldman Sachs Group lifted their price objective on AstraZeneca from GBX 5,000 ($65.33) to GBX 5,500 ($71.87) and gave the stock a “sell” rating in a research report on Monday, August 5th. Finally, Citigroup reiterated a “buy” rating and issued a GBX 7,000 ($91.47) price objective on shares of AstraZeneca in a research report on Monday, May 13th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus price target of GBX 6,688.24 ($87.39).

Shares of AZN stock opened at GBX 7,230 ($94.47) on Wednesday. The stock has a 50-day moving average price of GBX 6,755.80 and a 200 day moving average price of GBX 6,227.49. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The firm has a market cap of $94.85 billion and a price-to-earnings ratio of 42.23. AstraZeneca has a 12 month low of GBX 5,312 ($69.41) and a 12 month high of GBX 7,349.30 ($96.03).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Diversification

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.